Healthcare
Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s
Eli Lilly and Novo are developing new amylin drugs that serve as another biological lever to pull in treating obesity and diabetes.
Phrase
Obesity drugs
No market stories in the last 7 days. The latest coverage is below.
- 7-day mood
- —Not enough data
- Stories, 7 days
- 0
- Last 24 hours
- 0no baseline yet
- Sources
- 11in the latest 30
Mood and coverage · last 7 days
Market chart- Obesity drugs · 6-hour average
- Hourly reading
- Stories per hour
No scored stories in the last 7 days.
View as table
| Day | Mood | Stories |
|---|---|---|
| Sat, Oct 10 | — | 0 |
| Fri, Oct 9 | — | 0 |
| Thu, Oct 8 | — | 0 |
| Wed, Oct 7 | — | 0 |
| Tue, Oct 6 | — | 0 |
| Mon, Oct 5 | — | 0 |
| Sun, Oct 4 | — | 0 |
| Sat, Oct 3 | — | 0 |
Latest on Obesity drugs
Newest firstHealthcare
Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s
As Novo works to turn itself around, some analysts say Lilly has advantages that could help it maintain its position at the top of the obesity drug market.
Healthcare
STAT+: FDA approves AstraZeneca breast cancer drug
Roivant drug delivers mid-stage results, Moonwalk raises funds to develop longer-lasting obesity drugs, and more biotech news
Healthcare
Obesity drugs show early promise against the hormonal disorder PMOS, giving a suffering family hope
A small but growing body of research shows that GLP-1 drugs often used to treat obesity may also work for the hormonal disorder known as PMOS
Healthcare
Lilly sues six companies over alleged illegal sales of experimental obesity drug retatrutide
The lawsuits target a range of businesses that allegedly marketed retatrutide products to consumers despite the drug remaining under clinical development.
Healthcare
Kailera points to Phase III oral obesity drug data as it tees up Foundayo rivalry
Kailera's in-licensed oral weight loss drug is currently in a global Phase II study for obesity.
Healthcare
Medicare will start covering obesity drugs for the first time. Here's what patients should know
The move could unlock millions of new patients for Novo Nordisk and Eli Lilly and expand access to medications that were previously out of reach for seniors.
Healthcare
Seniors in Medicare are about to get landmark obesity drug coverage - but many may not know it yet
Many seniors may be unaware of the landmark coverage shift starting on July 1, with limited advertising seen from the government or Eli Lilly and Novo.
Healthcare
Obesity drugs approach a major milestone, and Lilly may have a 'game changer' ahead
Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of trading.
Healthcare
Drugmakers race to find a place in the next wave of obesity drugs
Drugmakers are betting they can crack into the obesity drug market that Novo Nordisk and Eli Lilly currently dominate.
Healthcare
Eli Lilly (LLY) Is Up 6.0% After Obesity Drug Data And $4.5B Manufacturing Push - Has The Bull Case Changed?
Earlier this week, Eli Lilly reported detailed late-phase obesity trial results showing long-term weight maintenance with injectable Zepbound and oral Foundayo…
Healthcare
Hot Picks: Pharma stocks gain on obesity drug demand
Pharma stocks are gaining momentum as obesity drugs, oncology therapies and biotech innovation boost investor optimism.
Healthcare
Neurocrine wants to develop new obesity drugs. It's making an acquisition to accelerate that move.
Soleno Therapeutics' stock is soaring on Monday in premarket after a report that Neurocrine is nearing a deal to buy the company.
Healthcare
Eli Lilly's next-generation obesity drug retatrutide clears first late-stage diabetes trial
Lilly is betting big on retatrutide as the next pillar of its obesity portfolio after its weight loss injection Zepbound and its upcoming pill, orforglipron.
Healthcare
Eli Lilly launches program to help boost employer coverage of obesity drugs in U.S.
Employers can use Lilly's platform to connect with different third-party program administrators that help manage obesity treatment benefits and costs.
Healthcare
Eli Lilly launches new form of obesity drug Zepbound with a month's worth of doses in one pen
Eli Lilly hopes the device can be more convenient for Zepbound users and lead to more people taking the drug.
Healthcare
Novo Nordisk CEO sees 15 million-patient opportunity in Medicare coverage for obesity drugs
Doustdar said Medicare coverage and the launch of Novo's new obesity pill should help gradually boost prescription volumes and offset lower prices in the U.S.
Healthcare
Eli Lilly's next-generation obesity drug delivers strong weight loss, reduces knee pain in late-stage trial
The drugmaker is betting big on retatrutide as the next pillar of its obesity portfolio after its weight loss injection Zepbound and its upcoming pill.
Healthcare
Novo's next-gen obesity drug shows positive results, heads to late-stage testing
Novo Nordisk said its experimental drug, amycretin, showed statistically significant weight loss of up to 14.5% at 36 weeks in patients with type 2 diabetes.
Healthcare
Kennedy Walks a Tightrope on Trump Deal for Obesity Drugs
The weight loss medicines are proving to be a test case for Robert F. Kennedy Jr., the health secretary, in straddling divisions between his supporters and the…
Healthcare
Pfizer wins $10 billion bidding war for obesity drug developer
Metsera accepted a sweetened offer from Pfizer late on Friday, citing U.S. antitrust risks in Novo's bid that it had previously called superior.
Healthcare
Pfizer clinches deal for obesity drug developer Metsea after a bidding war with Novo Nordisk
Pfizer has signed a deal to purchase Metsera Inc., an obesity drugmaker in the development stage, after winning a bidding war against Novo Nordisk
Healthcare
Pfizer to Acquire Obesity Drug Start-Up Metsera in $10 Billion Deal
The announcement of the deal signaled an end to the bidding war for Metsera between Pfizer and Novo Nordisk, the Danish maker of Ozempic and Wegovy.
Healthcare
Millions more Americans could access obesity drugs after Trump's deals with Eli Lilly, Novo Nordisk
Medicare will start covering obesity drugs for the first time, which could open access to millions of seniors and spur more private insurers to follow suit.
Healthcare
Trump Announces Deal to Drop Obesity Drug Prices to as Little as $150 a Month
President Trump announced a deal with Eli Lilly and Novo Nordisk to lower prices on hugely popular weight-loss drugs for Medicare, Medicaid and American patien…
Healthcare
Eli Lilly to start late-stage trials on amylin obesity drug after it shows up to 20% weight loss in study
The highest dose of Eli Lilly's weekly injection helped patients with obesity or who are overweight lose 20.1% of their body weight on average at 48 weeks.
Healthcare
Medicare recipients may get obesity drugs for just $149 a month under a reported White House deal in the works
The White House is close to announcing a deal with drugmakers Eli Lilly and Novo Nordisk that would cut the price of obesity drugs to $149 per month in some ca…
Healthcare
White House nears deal to lower obesity drug prices for Medicare coverage
The GLP-1 drugs, produced by Novo Nordisk and Eli Lilly, have been credited with helping weight-loss, preventing diabetes and other positive effects.
Healthcare
Pfizer sues Metsera, Novo Nordisk over rival obesity drug bid
Pfizer said Friday it filed a lawsuit against Metsera and Novo Nordisk saying Metsera breached its merger agreement obligations.
Healthcare
Pfizer boosts obesity drug prospects with $7.3 billion deal to buy Metsera
Metsera, founded in 2022, brings a pipeline of both oral and injectable treatments with different targets that could boost Pfizer's odds of entering the market.
